New Leaf Venture Partners Has Trimmed Its Position in Sage Therapeutics (SAGE) by $3.26 Million as Share Value Declined; As Mam Software Group (MAMS) Market Valuation Declined, Holder Cove Street Capital Has Lifted Position

May 18, 2018 - By Linda Rogers

Sage Therapeutics, Inc. (NASDAQ:SAGE) Logo

Robert Boucai decreased its stake in Sage Therapeutics Inc (SAGE) by 44.29% based on its latest 2017Q4 regulatory filing with the SEC. New Leaf Venture Partners Llc sold 19,872 shares as the company’s stock declined 6.84% with the market. The hedge fund run by Robert Boucai held 25,000 shares of the health care company at the end of 2017Q4, valued at $4.12 million, down from 44,872 at the end of the previous reported quarter. New Leaf Venture Partners Llc who had been investing in Sage Therapeutics Inc for a number of months, seems to be less bullish one the $7.70 billion market cap company. The stock decreased 5.57% or $9.77 during the last trading session, reaching $165.56. About 568,473 shares traded or 19.01% up from the average. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 135.95% since May 18, 2017 and is uptrending. It has outperformed by 124.40% the S&P500.

Jeffrey Bronchick increased its stake in Mam Software Group Inc (MAMS) by 20.72% based on its latest 2017Q4 regulatory filing with the SEC. Cove Street Capital Llc bought 107,586 shares as the company’s stock declined 0.61% with the market. The hedge fund run by Jeffrey Bronchick held 626,786 shares of the technology company at the end of 2017Q4, valued at $4.71 million, up from 519,200 at the end of the previous reported quarter. Cove Street Capital Llc who had been investing in Mam Software Group Inc for a number of months, seems to be bullish on the $102.26M market cap company. The stock decreased 0.12% or $0.01 during the last trading session, reaching $8.12. About 4,021 shares traded. MAM Software Group, Inc. (NASDAQ:MAMS) has risen 21.09% since May 18, 2017 and is uptrending. It has outperformed by 9.54% the S&P500.

Investors sentiment increased to 1.49 in 2017 Q4. Its up 0.28, from 1.21 in 2017Q3. It is positive, as 27 investors sold SAGE shares while 56 reduced holdings. 63 funds opened positions while 61 raised stakes. 41.45 million shares or 7.53% more from 38.55 million shares in 2017Q3 were reported. Swiss Bancorporation invested 0.01% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Bankshares Of America De accumulated 0% or 67,090 shares. Strs Ohio holds 0.02% in Sage Therapeutics, Inc. (NASDAQ:SAGE) or 28,600 shares. Ghost Tree Capital Ltd Liability invested 0.83% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Reilly Advsrs Ltd Liability Company holds 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 77 shares. 11,752 were reported by Metropolitan Life Ins New York. Great West Life Assurance Can reported 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Bank Of Ny Mellon Corporation has 1.62M shares for 0.07% of their portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) has 2,078 shares. Amalgamated Bancshares holds 0.02% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 5,147 shares. Cwm Limited Liability Company has 6 shares. Mirae Asset Global Invs reported 0.01% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Sectoral Asset Mgmt reported 17,200 shares. 1,343 are held by Comerica Bankshares. Castleark Mngmt Ltd invested 0.14% in Sage Therapeutics, Inc. (NASDAQ:SAGE).

Since December 14, 2017, it had 0 insider purchases, and 6 selling transactions for $42.42 million activity. $10.00 million worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) shares were sold by PAUL STEVEN M. $4.02M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) was sold by IGUCHI KIMI. FRATES JAMES M also sold $1.08M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) on Tuesday, May 8. On Tuesday, April 17 the insider STARR KEVIN P sold $9.96 million. On Thursday, December 14 Robichaud Albert sold $9.57M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) or 60,000 shares.

Among 18 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 16 have Buy rating, 0 Sell and 2 Hold. Therefore 89% are positive. SAGE Therapeutics had 57 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was initiated by Goldman Sachs on Wednesday, March 30 with “Neutral”. The company was initiated on Friday, March 11 by Lake Street. SunTrust maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) on Tuesday, February 27 with “Buy” rating. BMO Capital Markets maintained the stock with “Buy” rating in Thursday, November 9 report. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Buy” rating given on Tuesday, September 12 by Stifel Nicolaus. The firm has “Buy” rating by RBC Capital Markets given on Thursday, November 2. BMO Capital Markets maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) on Thursday, September 14 with “Outperform” rating. As per Thursday, October 19, the company rating was maintained by SunTrust. The rating was maintained by SunTrust with “Buy” on Thursday, December 7. On Tuesday, September 12 the stock rating was maintained by Cowen & Co with “Buy”.

Analysts await Sage Therapeutics, Inc. (NASDAQ:SAGE) to report earnings on August, 2. They expect $-1.87 earnings per share, up 0.53% or $0.01 from last year’s $-1.88 per share. After $-1.68 actual earnings per share reported by Sage Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 11.31% negative EPS growth.

More notable recent Sage Therapeutics, Inc. (NASDAQ:SAGE) news were published by: Streetinsider.com which released: “SAGE Therapeutics (SAGE) Defended at Raymond James, Says Selloff is Overreaction” on April 20, 2018, also Seekingalpha.com with their article: “Key events next week – healthcare” published on April 20, 2018, Seekingalpha.com published: “Sage Therapeutics 2018 Q1 – Results – Earnings Call Slides” on May 03, 2018. More interesting news about Sage Therapeutics, Inc. (NASDAQ:SAGE) were released by: Nasdaq.com and their article: “Why Stanley Black & Decker, ManpowerGroup, and Sage Therapeutics Slumped Today” published on April 20, 2018 as well as Streetinsider.com‘s news article titled: “Omega’s 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More…)” with publication date: May 15, 2018.

Another recent and important MAM Software Group, Inc. (NASDAQ:MAMS) news was published by Seekingalpha.com which published an article titled: “MAM Software Group’s (MAMS) CEO, Mike Jamieson on Q3 2018 Results – Earnings Call Transcript” on May 11, 2018.

Among 2 analysts covering Mam Software Group (NASDAQ:MAMS), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Mam Software Group had 4 analyst reports since November 12, 2015 according to SRatingsIntel. As per Monday, October 2, the company rating was maintained by B. Riley & Co. The firm has “Neutral” rating given on Thursday, November 12 by B. Riley & Co. The firm has “Neutral” rating given on Monday, February 12 by B. Riley & Co.

Investors sentiment increased to 2.5 in Q4 2017. Its up 0.50, from 2 in 2017Q3. It increased, as 0 investors sold MAMS shares while 2 reduced holdings. 3 funds opened positions while 2 raised stakes. 3.94 million shares or 3.16% more from 3.82 million shares in 2017Q3 were reported. Wynnefield Cap has invested 8.5% of its portfolio in MAM Software Group, Inc. (NASDAQ:MAMS). 500 are held by Royal Bancshares Of Canada. Cove Street Cap Ltd Liability invested 0.51% in MAM Software Group, Inc. (NASDAQ:MAMS). Moreover, Blackrock has 0% invested in MAM Software Group, Inc. (NASDAQ:MAMS). Panagora Asset Mgmt holds 0% or 2,694 shares in its portfolio. Acadian Asset Limited owns 1,071 shares. Moreover, Deutsche Retail Bank Ag has 0% invested in MAM Software Group, Inc. (NASDAQ:MAMS) for 7,552 shares. Minerva Advisors Lc holds 0.04% or 10,330 shares.

Since December 18, 2017, it had 0 buys, and 3 selling transactions for $2.45 million activity. Shares for $921,100 were sold by Lewis William Austin IV.

Cove Street Capital Llc, which manages about $763.78 million and $926.82M US Long portfolio, decreased its stake in Par Pacific Holdings Inc (NYSEMKT:PARR) by 20,000 shares to 55,000 shares, valued at $1.06 million in 2017Q4, according to the filing. It also reduced its holding in Frp Holdings Inc by 10,000 shares in the quarter, leaving it with 25,000 shares, and cut its stake in Usg Corp (NYSE:USG).

MAM Software Group, Inc. (NASDAQ:MAMS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.